In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Navigating shifting paradigms in dose optimisation and dose selection for oncology therapeutics
In this article, ICON expert, Tim Clark, discuss the shift in paradigms in dose optimisation and dose selection for oncology therapeutics.
-
Innovations contributing to the re-emergence of antibody drug conjugates
“ADCs are emerging as one of the fastest-growing segments of pharmaceuticals in 2024, the number of FDA approvals are likely to accelerate, revealing new treatment pathways and new problems to solve along the way.” Learn more in this article with the Clinical Oncologist Daily.
-
Leveraging Healthcare Intelligence to increase diversity of oncology clinical trials
This article in the Clinical Oncologist Daily, provides as overview on leveraging healthcare intelligence to increase diversity of oncology clinical trials.
-
Navigating oncology development decisions for long-term success
In this media article, ICON expert Tanja Obradovic, PhD, highlights how mapping clear inflection points for data-driven decisions will inform efficient drug development.
-
Paediatric clinical trials for obesity treatment
In this article, ICON experts Alan Baldridge and Heather Peterson discuss the prevalence of paediatric obesity and assess clinical trials of its treatments.
-
One direction
In this piece from PharmaTimes, Connie Inguanti, President at Symphony Health, an ICON plc company, discusses shaping a culture that allows customers to embrace an abundance of pivotal data.
-
.jpg?w=545&itok=sooA3iny "EPR-Logo-Thumbnail-(1)")
Pharma Horizons: Cell and Gene Therapy
In this report, experts in the field including ICON's Patricia Fox Anderson and Emily Merrell explore some of the latest innovations in the cell and gene therapy space, from development and quality control, through to manufacturing and clinical trials.
-
Current state of drug development, clinical trials and precision measures
This article in the Journal of mHealth, provides an overview of a recent npj Nature publication, that proposes enough alignment exists between independent traditional COA and DHT libraries to build a single framework for researchers to identify and compare actively-collected versus passively-monitored tools for the same or similar measure. Article is by Caprice Sassano, Research Lead – Applied Sciences at HumanFirst, an ICON company, with collaboration from Dr. Roya Sherafat, Scientific Director, MAPI Research Trust and Marcelo Alves Favaro, Associate Outcomes Researcher, MAPI Research Trust.
-
Making the most of biodata in remote studies
In this piece, Rosie Abbott explores how advances in technology have opened up many new opportunities and challenges in research, including the collection of biodata in remote studies. (see page 9)
-
ICON experts tackle specialty drug access challenges at AXS24
In this article, Angela Lawrence, Senior Director of RWE, Joe Brown, Principal Medical and Market Research, and Mark McCoy, RPh, MBA, Director Market Access and Reimbursement discuss the challenges of managing high-cost specialty drugs and how they influence self-funded employer benefit plan design and employee access to specialty medications.
.jpg?w=340&itok=lEKYSoCe "EPR-Logo-Thumbnail-(1)"){kind=icon}
